Evidence map›Paper›PMID 36556399›Full record

ArticleLife (Basel, Switzerland)2022

Butyrate Supplementation Exacerbates Myocardial and Immune Cell Mitochondrial Dysfunction in a Rat Model of Faecal Peritonitis.

Vera B M Peters, Nishkantha Arulkumaran, Miranda J Melis, Charlotte Gaupp, Thierry Roger, Manu Shankar-Hari, Mervyn Singer

Open access · goldAbstract read
In one paragraph

Article in Life (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Vera B M PetersBloomsbury Institute of Intensive Care Medicine, Division of Medicine, University College London, London WC1E 6BT, UK.ORCID 0000-0003-1067-7392
Nishkantha ArulkumaranBloomsbury Institute of Intensive Care Medicine, Division of Medicine, University College London, London WC1E 6BT, UK.
Miranda J MelisBloomsbury Institute of Intensive Care Medicine, Division of Medicine, University College London, London WC1E 6BT, UK.ORCID 0000-0002-3913-4597
Charlotte GauppBloomsbury Institute of Intensive Care Medicine, Division of Medicine, University College London, London WC1E 6BT, UK.
Thierry RogerInfectious Diseases Service, Department of Medicine, Lausanne University Hospital and University of Lausanne, CH-1066 Lausanne, Switzerland.ORCID 0000-0002-9358-0109
Manu Shankar-HariCentre for Inflammation Research, Institute for Regeneration and Repair, The University of Edinburgh, Edinburgh EH16 4TJ, UK.ORCID 0000-0002-5338-2538
Mervyn SingerBloomsbury Institute of Intensive Care Medicine, Division of Medicine, University College London, London WC1E 6BT, UK.
Bury College · GBCentre for Inflammation Research · GBUniversity of Lausanne · CH

Funding

European Sepsis Academy Horizon 2020 Marie Skłodowska-Curie Action: Innovative Training Network 676129Fondation Carigest/Promex Stiftung für die Forschung (Genève, Switzerland)Swiss National Science Foundation 310030_173123UK National Institute of Health Research (NIHR) European Society of Intensive Care Medicine (ESICM) NEXT start up Award
6 · The paper itself

Abstract

Mitochondrial dysfunction and immune cell dysfunction are commonplace in sepsis and are associated with increased mortality risk. The short chain fatty acid, butyrate, is known to have anti-inflammatory effects and promote mitochondrial biogenesis. We therefore explored the immunometabolic effects of butyrate in an animal model of sepsis. Isolated healthy human volunteer peripheral mononuclear cells were stimulated with LPS in the presence of absence of butyrate, and released cytokines measured. Male Wistar rats housed in metabolic cages received either intravenous butyrate infusion or placebo commencing 6 h following faecal peritonitis induction. At 24 h, splenocytes were isolated for high-resolution respirometry, and measurement of mitochondrial membrane potential (MMP), reactive oxygen species (mtROS), and intracellular cytokines (TNF alpha, IL-10) using flow cytometry. Isolated splenocytes from septic and septic butyrate treated rats were stimulated with LPS for 18 h and the effects of butyrate on cytokine release assessed. Ex vivo, butyrate (1.8 mM) reduced LPS-induced TNF alpha (p = 0.019) and IL-10 (p = 0.001) release by human PBMCs. In septic animals butyrate infusion reduced the respiratory exchange ratio (p < 0.001), consistent with increased fat metabolism. This was associated with a reduction in cardiac output (p = 0.001), and increased lactate (p = 0.031) compared to placebo-treated septic animals (p < 0.05). Butyrate treatment was associated with a reduction in splenocyte basal respiration (p = 0.077), proton leak (p = 0.022), and non-mitochondrial respiration (p = 0.055), and an increase in MMP (p = 0.007) and mtROS (p = 0.027) compared to untreated septic animals. Splenocyte intracellular cytokines were unaffected by butyrate, although LPS-induced IL-10 release was impaired (p = 0.039). In summary, butyrate supplementation exacerbates myocardial and immune cell mitochondrial dysfunction in a rat model of faecal peritonitis.

Indexed as

butyratefatty acidsimmunitymitochondrianutritionsepsis

Identifiers

PMID36556399
PMCPMC9785094
OpenAlexW4311633458

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.